Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov 19;11(11):1077.
doi: 10.3390/v11111077.

HBV Infection in HIV-Driven Immune Suppression

Loredana Sarmati  1 , Vincenzo Malagnino  1
Affiliations
Review

HBV Infection in HIV-Driven Immune Suppression

Loredana Sarmati et al. Viruses. .

Abstract

Worldwide, approximately 10% of all human immunodeficiency virus (HIV)-infected people are also chronically coinfected with hepatitis B virus (HBV). HBV infection has a poor prognosis in HIV-positive people and has been documented by an increased risk of developing chronic HBV infection (CHB), progression to liver fibrosis and end-stage liver disease (ESLD) and evolution of hepatocellular carcinoma (HCC). Furthermore, in HIV patients, HBV-resolved infection is often associated with the appearance of HBV-DNA, which configures occult HBV infection (OBI) as a condition to be explored in coinfected patients. In this narrative review we summarize the main aspects of HBV infection in HIV-positive patients, emphasizing the importance of carefully considering the coinfected patient in the context of therapeutic strategies of antiretroviral therapy.

Keywords: HIV/HBV coinfection; end-stage liver disease; hepatitis B virus; hepatocellular carcinoma; occult HBV infection.

PubMed Disclaimer

Conflict of interest statement

There were no potential conflicts of interest in the drafting of the paper. V.M. has served on the advisory board for Janssen Cilad. L.M. has received travel grants from Gilead, Merck, Bristol, and Pfizer; received payment for lectures from Merck, Gilead, Bristol, and Abbvie; received consulting fees from Angelini SpA; and received research funding from Gilead.

References

    1. Global HIV & AIDS Statistics—2019 Fact Sheet. [(accessed on 16 November 2019)]; Available online: https://www.unaids.org/en/resources/fact-sheet.
    1. Ganesan M., Poluektova L.Y., Kharbanda K.K., Osna N.A. Human immunodeficiency virus and hepatotropic viruses co-morbidities as the inducers of liver injury progression. World J. Gastroenterol. 2019;25:398–410. doi: 10.3748/wjg.v25.i4.398. - DOI - PMC - PubMed
    1. Sun H.-Y. Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: A review. World J. Gastroenterol. 2014;20:14598. doi: 10.3748/wjg.v20.i40.14598. - DOI - PMC - PubMed
    1. Singh K.P., Crane M., Audsley J., Avihingsanon A., Sasadeusz J., Lewin S.R. HIV-hepatitis B virus coinfection: Epidemiology, pathogenesis, and treatment. AIDS. 2017;31:2035–2052. doi: 10.1097/QAD.0000000000001574. - DOI - PMC - PubMed
    1. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., Huang G.T., Iloeje U.H. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73. doi: 10.1001/jama.295.1.65. - DOI - PubMed